Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | HTR2B | P41595 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 6/20 | 0.42 |
| ▸ | DNM2 | P50570 | 4/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361303 | 0.86 | HTR2C (0.75) | HTR2CHTR2AHTR2BHTR1AHTR6 | |
| SCHEMBL23723408 | 0.86 | HTR2C (0.75) | HTR2CHTR2AHTR2BHTR1AHTR6 | |
| SCHEMBL30356554 | 0.84 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1AHTR6 | |
| SCHEMBL29405683 | 0.84 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1AHTR6 | |
| SCHEMBL23805226 | 0.79 | HTR2A (1.00) | HTR2CHTR2AHTR2BHTR1AHTR6 | |
| SCHEMBL23805220 | 0.79 | HTR2A (0.65) | HTR2CHTR2AHTR2BHTR6DNM2 | |
| SCHEMBL23723381 | 0.79 | HTR2A (0.65) | HTR2CHTR2AHTR2BHTR1AHTR6 | |
| SCHEMBL25074655 | 0.77 | HTR2C (0.69) | HTR2CHTR2AHTR2BHTR1AHTR6 | |
| SCHEMBL3176621 | 0.74 | HTR2C (0.59) | HTR2CHTR2AHTR2BHTR1AHTR6 | |
| SCHEMBL31188169 | 0.74 | HTR2C (0.59) | HTR2CHTR2AHTR2BHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366638-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | SYNAPTIVE THERAPEUTICS, LLC | 2024-11-07 | — | — | US | disclosed |
| US-20230405026-A1 | A Method of Treating Depression by Immune Modulation | MYND LIFE SCIENCES INC (CA) | 2023-12-21 | — | — | US | disclosed |
| WO-2021155467-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366638-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | HTR1B, HTR2B, PNMT | HTR2C 4/4885HTR2A 5/4885HTR2B 2/4885 |
| US-20230405026-A1 | A Method of Treating Depression by Immune Modulation | ABCF1, ABCF2, ABCB4 | HTR2C 1196/4885HTR2A 377/4885HTR2B 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.